PATENT CLAIM ANALYSIS

Application Number: 15873473
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "489000"]

Abstract:
The present invert on relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

Claim (Index 15):
A process of manufacturing microparticles according to  claim 1  comprising\n (i) preparation of an internal organic phase comprising\n (ia) dissolving the two or more different PLGA polymers suitable organic solvent or solvent mixture; \n (ib) dissolving/suspending/emulsification of octreotide or a pharmaceutically-acceptable salt thereof in the polymer solution obtained in step (ia); \n \n (ii) preparation of an external aqueous phase containing stabilizers: \n (iii) mixing the internal organic phase with the external aqueous phase to form an emulsion; and \n (iv) hardening the microparticles by solvent evaporation or solvent extraction, washing the microparticles, drying the microparticles and sieving the microparticles.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 86.0
- Lexical Diversity: 1.03448
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13472219', '10565401', '13408472', '10564494', '13258808']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6513838037276464
- 35 USC 102 Novelty (BERT): 0.5827418140221587
- Combined Prediction Score: 0.6445196047570976
- Mean Citation Score: 280.17915400000004
- Max Citation Score: 477.6233
- Similarity Product: 410.511272092247

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test